Type | Therapy | Primary Outcome | Inclusion | Clinicaltrials.gov Identifier |
---|---|---|---|---|
Phase 1 | Nivolumab +/− ipilimumab or lirilumab | Safety | Relapsed/refractory NHL and HL | NCT01592370 |
Phase 1 | Ipilimumab, nivolumab and brentuximab vedotin | Safety | Relapsed/refractory HL | NCT01896999 |
Phase 1 | Ipilimumab or nivolumab post allo-SCT | Safety | Relapsed/refractory NHL and HL | NCT01822509 |
Phase 1 | Ipilimumab post allo-SCT | GVHD and graft rejection | Relapsed/refractory NHL and HL | NCT00060372 |
Phase 1 | Ipilimumab + lenalidomide post allo- or auto-SCT | Safety, including GVHD | NHL and HL | NCT01919619 |
Phase 1 | Pembrolizumab | Safety and objective response rate | Relapsed/refractory NHL and HL | NCT01953692 |
Phase 1 | Pembrolizumab + chemotherapy | Safety and TRM | Untreated DLBCL | NCT02541565 |
Phase 1 | Pembrolizumab + dinaciclib | Safety | Relapsed/refractory NHL | NCT02684617 |
Phase 1/2 | Nivolumab +/− Ipilimumab | Safety and response rate | Relapsed/refractory NHL and HL | NCT02304458 |
Phase 1/2 | Nivolumab + brentuximab | Toxicity and response rate | Relapsed/refractory HL | NCT02572167 |
Phase 1/2 | Nivolumab + urelumab | Toxicity and efficacy | Relapsed/refractory NHL | NCT02253992 |
Phase 1/2 | Nivolumab + epacadostat | Toxicity, ORR and PFS | Relapsed/refractory NHL and HL | NCT02327078 |
Phase 1/2 | Pembrolizumab + epacadostat | Safety and ORR | Relapsed/refractory NHL | NCT02178722 |
Phase 1/2 | Pembrolizumab post CD19 CAR T cell therapy | Safety | Relapsed/refractory NHL | NCT02650999 |
Phase 2 | Nivolumab + brentuximab | Metabolic response rate | Elderly with untreated HL | NCT02758717 |
Phase 2 | Nivolumab post auto-SCT | Objective and overall response rates | Classic HL | NCT02181738 |
Phase 2 | Pembrolizumab | Objective response rate | Relapsed/refractory primary mediastinal lymphoma or Richter syndrome | NCT02576990 |
Phase 2 | Pembrolizumab | Efficacy | Recurrent CNS lymphoma | NCT02779101 |
Phase 2 | Pembrolizumab | PFS | Relapsed/refractory T-cell NHL | NCT02535247 |
Phase 2 | Pembrolizumab + rituximab | ORR | Follicular lymphoma | NCT02446457 |
Phase 2 | Pembrolizumab + idelalisib or ibrutinib | Response rate | Low grade NHL | NCT02332980 |
Phase 2 | Pembrolizumab post auto-SCT | PFS | Relapsed/refractory NHL and HL | NCT02362997 |
Phase 2 | Pidilizumab | Response | Stage III-IV DLBCL in first remission | NCT02530125 |
allo-SCT, allogeneic stem cell transplantation; auto-SCT, autologous stem cell transplantation; CAR, chimeric antigen receptor; CNS, central nervous system; DLBCL, diffuse large b cell lymphoma; GVHD, graft versus host disease; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; ORR, overall response rate; PFS, progression free survival; TRM, treatment related mortality.